In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae
Authors:
Open Access
- 1 February 1992
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 36 (2) , 291-294
Abstract
The in vitro activities of azithromycin (CP-62,993; Pfizer), erythromycin, and tetracycline were evaluated by inhibiting Chlamydia trachomatis and Chlamydia pneumoniae, formerly TWAR, propagation in vitro in McCoy cells, HeLa cells, and HL cells. Eleven clinical isolates of C. trachomatis (serovars D, E, F, J, K, and L2) and four strains of C. pneumoniae were tested with an inoculum of 10(3) inclusion-forming units in a 96-well microtiter plate. The MIC ranges of these antimicrobial agents against C. trachomatis were as follows: azithromycin, 0.125 to 0.5 microgram/ml; erythromycin, 0.25 to 0.1 microgram/ml; and tetracycline, 0.0625 to 1.0 microgram/ml. The MBC ranges, calculated from passage into antibiotic-free medium, were as follows: azithromycin, 0.125 to 4.0 micrograms/ml; erythromycin, 0.5 to 8.0 micrograms/ml; and tetracycline, 0.0625 to 4.0 micrograms/ml. The MIC ranges for C. pneumoniae in both HeLa and HL cells were as follows: azithromycin, 0.125 to 1.0 micrograms/ml; erythromycin, 0.0625 to 1.0 microgram/ml; and tetracycline, 0.125 to 1.0 microgram/ml. The MBC ranges were as follows: azithromycin, 0.25 to 1.0 microgram/ml; erythromycin, 0.25 to 1.0 microgram/ml; and tetracycline, 0.125 to 4.0 micrograms/ml. From the results of this in vitro study, azithromycin appears to be an effective antibiotic comparable to tetracycline and erythromycin for use in the treatment of both C. trachomatis and C. pneumoniae infections.Keywords
This publication has 9 references indexed in Scilit:
- Partial Characterization of Chlamydia trachomatis Isolates Resistant to Multiple AntibioticsThe Journal of Infectious Diseases, 1990
- In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR)Antimicrobial Agents and Chemotherapy, 1989
- In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolonesAntimicrobial Agents and Chemotherapy, 1988
- In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatisAntimicrobial Agents and Chemotherapy, 1987
- A NewChlamydia psittaciStrain, TWAR, Isolated in Acute Respiratory Tract InfectionsNew England Journal of Medicine, 1986
- ASSESSING THE NUMBER OF GENITAL CHLAMYDIAL INFECTIONS IN THE UNITED-STATES1985
- Treatment of Chlamydial Urethritis in Men and Chlamydia trachomatis-pos/f/Ve Female PartnersSexually Transmitted Diseases, 1982
- Relative resistance to erythromycin in Chlamydia trachomatisAntimicrobial Agents and Chemotherapy, 1980
- Antibiotic Susceptibility of Chlamydia trachomatisAntimicrobial Agents and Chemotherapy, 1977